ReviewLancet (London, England)2022
Influenza.
Review in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 319 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
319 citing papers in PubMed, 4 syntheses or guidelines pooled it, 473 citations in OpenAlex.
- Maternal influenza vaccination during the first trimester of pregnancy and risk for birth defects: an updated systematic review and meta-analysis.BMC pregnancy and childbirth · 2026Pooled it
- Clinical presentation of Oropouche virus infection: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.JAMA internal medicine · 2025Pooled it
- Influenza vaccine outcomes: a meta-analysis revealing morbidity benefits amid low infection prevention.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Comparison of safety and immunogenicity between high-dose and low-dose quadrivalent influenza vaccines in children aged 6-35 months in China: A randomized, double-blind clinical study.Human vaccines & immunotherapeutics · 2026Trial
- Oseltamivir for Treatment of Influenza Among Outpatient Veterans: Target Trial Emulation.Open forum infectious diseases · 2026Trial
- Reactogenicity, safety, and immunogenicity of a quadrivalent seasonal influenza vaccine in adults aged 65 years and older: Phase 4 study results from India during December 2023-February 2024.Human vaccines & immunotherapeutics · 2025Trial
- Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial.BMC medicine · 2025Trial
- Boosting effect of high-dose influenza vaccination on innate immunity among elderly.JCI insight · 2025Trial
- Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection.The Journal of infectious diseases · 2025Trial
- Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial.Human vaccines & immunotherapeutics · 2024Trial
- Epidemiological and virological characteristics of influenza in Zhejiang Province, China: A 15-year surveillance study.Human vaccines & immunotherapeutics · 2026Article
- Comparative analysis of parental hesitancy toward influenza vaccination for children versus themselves in post-pandemic China: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- The economic burden of seasonal influenza - China, 2010-2019.Human vaccines & immunotherapeutics · 2026Article
- Clinical Outcomes and Predictors of Adverse Events in Influenza Patients Managed in a Hospital-at-Home Program: A 10-Year Retrospective Study.American journal of medicine open · 2026Article
- Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.Emerging microbes & infections · 2026Article
- A CRISPR activation screen identifies CH25H as a restriction factor against influenza viruses by targeting accessible cholesterol.Emerging microbes & infections · 2026Article
- The effect of short message reminders on seasonal influenza vaccination rates in the geriatric population.Human vaccines & immunotherapeutics · 2026Article
- Delayed antiviral immune response in alveolar type 2 cells increases susceptibility to influenza virus in alveoli.Chinese medical journal · 2026Article
- Characterization of Seasonal Trivalent Influenza Vaccine Formulated with Different Ratios (Vaccines · 2026Article
259 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Annual seasonal influenza epidemics of variable severity caused by influenza A and B virus infections result in substantial disease burden worldwide. Seasonal influenza virus circulation declined markedly in 2020-21 after SARS-CoV-2 emerged but increased in 2021-22. Most people with influenza have abrupt onset of respiratory symptoms and myalgia with or without fever and recover within 1 week, but some can experience severe or fatal complications. Prevention is primarily by annual influenza vaccination, with efforts underway to develop new vaccines with improved effectiveness. Sporadic zoonotic infections with novel influenza A viruses of avian or swine origin continue to pose pandemic threats. In this Seminar, we discuss updates of key influenza issues for clinicians, in particular epidemiology, virology, and pathogenesis, diagnostic testing including multiplex assays that detect influenza viruses and SARS-CoV-2, complications, antiviral treatment, influenza vaccines, infection prevention, and non-pharmaceutical interventions, and highlight gaps in clinical management and priorities for clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.